Cure Alzheimer’s Fund announced that it has reached a significant milestone, awarding more than $125 million in research grants since its inception.
Since its founding in 2004, Cure Alzheimer’s Fund (CureAlz) has supported 540 innovative projects conducted by 175 dedicated scientists from institutions throughout the world, resulting in more than 800 published peer-reviewed papers. Many of these projects have yielded significant breakthroughs–resulting in hypotheses that may lead to new and critical avenues for the development of novel treatments.
An important area of study resulting from grants provided by Cure Alzheimer’s Fund is the Alzheimer’s Genome Project™. The project provides the foundation for other major genetic studies, adding pieces to the puzzle of the many genetic factors contributing to Alzheimer’s disease. For example, recent investigations led by Drs. Rudy Tanzi and Dmitry Prokopenko have revealed four novel sex-specific Alzheimer’s disease (AD) genes that confer opposite AD risk impact in men versus women. Variations in three of these genes increased AD risk in men but seemed to be protective in women.
Areas of study provided through grants from Cure Alzheimer’s Fund are detailed in the 2020 Annual Report found here https://curealz.org/news-and-events/2020-annual-report-is-now-available/
“For 17 years, the Board of Directors of Cure Alzheimer’s Fund has remained committed to allowing and encouraging researchers to follow the science and explore high risk / high reward hypotheses. Today, due to the commitment of so many devoted researchers, there is great momentum and new discoveries that will lead to therapies for Alzheimer’s disease. We are honored to have been the recipients of the generosity of more than 50,000 donors who have made this research possible, and continue to work on behalf of the 50 million worldwide who have been diagnosed with Alzheimer’s disease,” said Tim Armour, President and CEO of Cure Alzheimer’s Fund.